Press Releases August 26, 2026 08:00 AM

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

Odyssey Therapeutics Announces Participation in Multiple September Investor Conferences

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
ODTX

Odyssey Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, announced that its management team will participate in several investor conferences in September 2026, including Cantor Global Healthcare, Morgan Stanley Global Healthcare, and H.C. Wainwright Global Investment Conferences. The company highlights its ongoing clinical progress and portfolio advancements.

Odyssey Therapeutics to Participate in Upcoming Investor Conferences
ODTX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Odyssey Therapeutics is focusing on developing medicines targeting autoimmune and inflammatory diseases with unmet medical needs.
  • The company will engage with investors through multiple high-profile healthcare investment conferences this September, providing updates on clinical and development milestones.
  • Odyssey's strategy leverages scientific expertise and innovative tools to develop therapies aimed at durable remission in inflammatory conditions.
  • The biopharmaceutical sector and healthcare investment markets are directly impacted by these developments.

BOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that members of its management team will participate in the following upcoming investor conferences in September:

  • 2026 Cantor Global Healthcare Conference
    Conference Dates: September 9-11, 2026
    Location: New York, NY
    Fireside Chat: September 9th at 8:35AM ET
  • Morgan Stanley 24th Annual Global Healthcare Conference
    Conference Dates: September 14-16, 2026
    Location: New York, NY
    Fireside Chat: September 14th at 10:45AM ET
  • H.C. Wainwright 28th Annual Global Investment Conference
    Conference Dates: September 14-16, 2026
    Location: New York, NY
    Fireside Chat: September 15th at 1:00PM ET

Where available, live webcasts will be available under “News and Events” in the Investors section of the Company’s website at www.odysseytx.com. Replays of the webcasts will be made available on the Events page of Odyssey’s investor website and archived for 60 days.

About Odyssey Therapeutics

Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of internally discovered and developed medicines with its first program advancing through multiple clinical milestones. Odyssey’s portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates that the Company believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need.

For more information, please visit https://odysseytx.com/ and follow Odyssey on LinkedIn or X.

Contacts

Investor Relations
Collin Todd
SVP, Strategy and Business Development
[email protected]


Risks

  • Clinical-stage status means ongoing development risks, including potential trial failures or delays impacting progress and valuation.
  • Market and investor interest might fluctuate depending on the clinical data and competitive landscape in autoimmune therapeutics.
  • General biotech sector volatility and regulatory uncertainties could affect Odyssey’s market performance and fundraising capabilities.

More from Press Releases

NeOnc’s Clinical Story Is Now the Main Event Aug 26, 2026 T3 Defense Subsidiary Tiltan to Deliver Majestic.ai as Licensed Software Aug 26, 2026 IntentKey Integrates FouAnalytics Verification to Help Advertisers Improve Programmatic Efficiency Aug 26, 2026 Heidmar Announces Date for the Second Quarter 2026 Financial Results, Conference Call, and Webcast Aug 26, 2026 QNB Corp. Declares Q3 2026 Dividend Aug 26, 2026